Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.905 USD | +3.06% | -1.97% | -37.79% |
May. 15 | HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating | MT |
May. 14 | Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.79% | 183M | |
+9.85% | 118B | |
+10.29% | 106B | |
-11.03% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.52% | 15.97B | |
+6.90% | 14.03B | |
+17.59% | 11.67B |
- Stock Market
- Equities
- FENC Stock
- News Fennec Pharmaceuticals Inc.
- Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively